Literature DB >> 7814510

Evaluation of a new reagent for anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G.

J Gutierrez1, M D Maroto, G Piédrola.   

Abstract

The Enzygnost alpha method was tested against the complement fixation test and anti-VCA immunofluorescence to determine the respective titers of anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G antibodies. For cytomegalovirus, the Enzygnost results showed 97.99% agreement with the readings obtained by the alternative method, with 100% sensitivity and 93.7% specificity. For Epstein-Barr virus, Enzygnost showed 97.71% agreement, 100% sensitivity, and 91.11% specificity.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7814510      PMCID： PMC264115          DOI： 10.1128/jcm.32.10.2603-2605.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Antibodies to cytomegalovirus, Herpes simplex virus and Epstein-Barr virus in Greek blood donors.

Authors:  L Kavallierou; E Bezirtzoglou; P Kapellou; S Spanaki; N Renieri
Journal:  Med Lab Sci       Date:  1991-04

2.  Cytomegalovirus infections in liver transplant patients: incidence and outcome.

Authors:  L M Barkholt; B G Ericzon; A Ehrnst; M Forsgren; J P Andersson
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Comparison of four methods for screening of cytomegalovirus antibodies in normal donors and immunocompromised patients.

Authors:  F de Ory; P León; C Domingo; A Garcia-Sáiz; L Pérez; J M Echevarría
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  [Cytomegalovirus: prevalence of antibodies in a control group].

Authors:  P Artieda; M I Cour; P Ortega; M C González-Sinde; M Giménez
Journal:  Rev Clin Esp       Date:  1986-06       Impact factor: 1.556

5.  Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome.

Authors:  S A Spector; K K Hirata; T R Newman
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

6.  IgG antibodies to cytomegalovirus in a normal urban Swedish population.

Authors:  K Ahlfors
Journal:  Scand J Infect Dis       Date:  1984

7.  Evaluation of the CMV-CUBE assay for detection of cytomegalovirus serologic status in marrow transplant patients and marrow donors.

Authors:  C A Gleaves; S F Wendt; D R Dobbs; J D Meyers
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

8.  A serological study of cytomegalovirus and herpes simplex virus infections in Peninsular Malaysia.

Authors:  D S Tan; H Stern
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

9.  A collaborative study of cytomegalovirus antibodies in mothers and young children in 19 countries.

Authors:  U Krech; J Tobin
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

10.  Virus-specific antibodies to Epstein-Barr virus, varicella-zoster virus and rubella virus in renal transplant patients with cytomegalovirus infections.

Authors:  H J O'Neill; P V Shirodaria
Journal:  J Infect       Date:  1992-05       Impact factor: 6.072
View more
  4 in total

1.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Antibodies to Borrelia burgdorferi in European populations.

Authors:  J Gutiérrez; M Guerrero; F Nuñez; M J Soto; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

3.  Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein-Barr virus infections in childhood.

Authors:  L Schaade; M Kleines; M Häusler
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA.

Authors:  J Gutiérrez; M J Vergara; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.